BARDA seeks proposals for late-stage antibiotic development to mitigate the threat of antibiotic resistant infections

About Image
Now accepting proposals to support a Project BioShield initiative for late-stage development, regulatory approval, and potential procurement of antibiotics for biothreat indications.  
On January 20, 2022, BARDA's Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures Division issued a Request for Proposals (RFP) solicitation for the development of antibiotics for a biothreat indication.
The prevalence of infections caused by antibiotic-resistant pathogens and the potential transfer, either natural or intentional, of these antibiotic-resistant genes to biothreat pathogens, are threats to the health security of the United States. Community- and hospital-acquired antibiotic-resistant infections can complicate the Department of Health and Human Services’ (HHS) response to public health emergencies, natural disasters, and CBRN threats. The illnesses and injuries caused by CBRN threats can lead to secondary bacterial infections, many of which can be caused by antibiotic resistant bacteria. Antibiotic resistance also has the potential to render antibacterial medical countermeasures (MCMs) for biothreat pathogens ineffective. Development and procurement of antibiotics that overcome known forms of resistance and treat biothreat pathogens will enhance the nation’s emergency preparedness.
To meet this need, BARDA is seeking proposals from small business sources to support the late-stage development, approval, and potential procurement of an antibiotic using funding authorization granted by the Project BioShield Act of 2004. BARDA seeks to support the marketing authorization of a novel antibiotic for the treatment (and, if feasible, post-exposure prophylaxis) of infections against one or more of the following pathogens: Yersinia pestis, Francisella tularensis, and Burkholderia pseudomallei. Products that expand the existing U.S. preparedness posture are the highest priority. The product must either have received marketing authorization from the U.S. Food and Drug Administration (FDA) within the last 10 years or be in Phase 3 clinical development for a commercial or biothreat indication.  
The anticipated contract award(s) will be part of BARDA's CBRN Antibacterial Medical Countermeasures Program that has supported over 30 advanced research and development public-private partnerships with industry, ranging from small biotechnology firms to global pharmaceutical companies, since 2010. 
All questions must be submitted by 12:00 PM ET on February 3, 2022. Proposals may be submitted until 4:00 PM ET on April 6, 2022. For additional information, see RFP 75A50122R00009 (PDF - 1,822KB) in the Antimicrobial Resistance Project BioShield: BARDA Antibiotic for AMR and Biothreat Pathogens solicitation.

Last Updated: January 21, 2022

CBRN Portfolio

The CBRN investments support advanced research and development and national security procurement of medical countermeasures to addresses national security threats. This award is one component of BARDA's CBRN medical countermeasure portfolio; visit the CBRN Portfolio to learn more.